Skip to main content
Erschienen in: BMC Cancer 1/2019

Open Access 01.12.2019 | Research article

Clinicopathologic predictors of metastasis of different regional lymph nodes in patients intraoperatively diagnosed with stage-I non-small cell lung cancer

verfasst von: Fei Zhao, Fu-Xi Zhen, Yue Zhou, Chen-Jun Huang, Yue Yu, Jun Li, Qi-Fan Li, Cheng-Xiang Zhu, Xiao-Yu Yang, Shu-Hui You, Qian-Ge Wu, Xue-Yun Qin, Yi Liu, Liang Chen, Wei Wang

Erschienen in: BMC Cancer | Ausgabe 1/2019

Abstract

Background

Selection of the best lymph node for dissection is a controversial topic in clinical stage-I non-small cell lung cancer (NSCLC). Here, we sought to identify the clinicopathologic predictors of regional lymph node metastasis in patients intraoperatively diagnosed with stage-I NSCLC.

Methods

A retrospective review of 595 patients intraoperatively diagnosed as stage I non-small-cell lung cancer who underwent lobectomy with complete lymph node dissection was performed. Univariate and multivariable logistic regression analysis was performed to determine the independent predictors of regional lymph node metastasis.

Results

Univariate logistic regression and multivariable analysis revealed three independent predictors of the presence of metastatic hilar lymph nodes, five independent predictors for lobe specific mediastinal lymph nodes, two independent predictors for lobe nonspecific mediastinal lymph nodes and two independent predictors for skipping mediastinal lymph nodes.

Conclusions

A complete mediastinal lymph node dissection may be considered for patients suspected of nerve invasion and albumin (> 43.1 g/L) or nerve and vascular invasions. Lobe-specific lymph node dissection should probably be performed for patients suspected of pulmonary membrane invasion, vascular invasion, CEA (> 2.21 ng/mL), and tumor (> 1.6 cm) in the right lower lobe or mixed lobes. Hilar lymph node dissection should probably be performed for patients suspected of having bronchial mucosa and cartilage invasion, vascular invasion, and CEA (> 2.21 ng/mL).
Begleitmaterial
Additional file 1: Support file containing the Age (G), cigarettes (0:negative, 1:positive), Alcohol (0:negative, 1:positive), chronic bronchitis (0:negative, 1:positive), diabetes (0:negative, 1:positive), tumor history (0:negative, 1:positive), tumor family history (0:negative, 1:positive), blood type (0:A,1:B,2:O,3:AB), Neutrophil(G), Lymphocyte(G), N/L(G), Platelet(G), Serum Albumin(G), ALP(G), Serum Globulin(G), Al/Gl ratio(G), APTT(G), PT(G), CEA(G), CYFRA211(G), NSE(G), Tumor size(G), Tumor location (0:right upper,1:right middle,2:right lower,3:left upper,4:left lower,5:Ipsilateral), Tumor location(G), Pathology (0:AdCa,1:SqCa,2:Adenocarcinoma in situ,3:other), Pathology(G),Grade (G), Pathological morphology (1:lepidic, 2:Acinar, 3:Micropapillary, 4:Papillary, 5:solid), Pathological morphology(G), Pulmonary membrane invasion (0:negative, 1:positive), Bronchial mucosa and cartilage invasion (0:negative, 1:positive), Vascular invasion (0:negative, 1:positive), Nerve invasion (0:negative, 1:positive), Lobe-specific mediastinal lymph nodes (1:metastasis 0:no metastasis),Lobe non-specific mediastinal lymph nodes (1:metastasis 0:no metastasis), skiping mediastinal lymph nodes (1:metastasis 0:no metastasis),2, 4station(1:metastasis 0:no metastasis),5, 6station(1:metastasis 0:no metastasis),7station(1:metastasis 0:no metastasis),8station(1:metastasis 0:no metastasis), 9station(1:metastasis 0:no metastasis), hilar lymph nodes (10 station)(1:metastasis 0:no metastasis), interlobe lymph nodes (11 station)(1,metastasis 0,no metastasis) described in categorical variables and Age ranges (yrs), number of cigarettes, Tumor size (cm). Neutrophil, Lymphocyte, N/L, Platelet, Serum Albumin, ALP, Serum Globulin, Al/Gl ratio, APTT, PT, CEA, CYFRA211, NSE described in continuous variables. (XLSX 173 kb)
Hinweise

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1186/​s12885-019-5632-2) contains supplementary material, which is available to authorized users.
Fei Zhao and Fu-Xi Zhen contributed equally to this work.
Abkürzungen
CEA
Carcinoembryonic antigen
CI
Confidence intervals
CT
Computed tomography
IASLC
Association for the study of lung cancer
MLN
Mediastinal lymph node
NCCN
National comprehensive cancer network
NSCLC
Non-small-cell lung cancer
OR
Odds ratio
pN
pathological nodal
TNM
Tumor, Node Metastases

Background

Patients diagnosed with stage-I non-small cell lung cancer (NSCLC) are most likely to be cured by surgical radical resection. Lymph node dissection is an important part of this procedure that can improve the prognosis of the patients in stage-I [1]. However, selection of the best strategy for lymph node dissection remains controversial.
In general, lymph nodes with short-axis diameters of > 1 cm as seen on CT scan are considered by the radiologists to represent metastasis when other reasons causing lymph node enlargement, such as chronic inflammation and tuberculosis, are excluded. Unfortunately, the diagnostic accuracy of CT scan for the preoperative lymph node stage is only 45–79% [26]. Also, 12–17% of patients pathologically diagnosed as N2 are preoperatively considered as N0. Skipping metastasis is also found in a part of these patients, as their CT scan results revealed lymph nodes with short-axis diameters of < 1 cm [4, 5, 7]. With technological developments, many methods, such as positron emission tomography, mediastinoscopy, and endoscopic ultrasound-guided fine-needle aspiration, are used to make accurate diagnosis when the surgeon ambiguously confirms preoperative lymph node metastasis. However, owing to the invasive nature of the procedure and the associated expenses, these diagnostic methods could not be routinely used for screening patients with clinical stage-I disease. Also, these procedures yield a considerable number of false-negative results and complications [810].
Although systematic nodal dissection can guarantee an accurate pathological nodal (pN) staging with a sufficient quantity of lymphatic tissue, the occurrence of postoperative complications will increase. For early stage patients, getting accurate patterns of lymph node dissection will decrease the postoperative complications and speed-up the patient recovery.
Regional lymph nodes attract attention for less invasive intraoperative lymph node dissection in early stage patients. We can classify the lymph nodes into four regional lymph nodes: Interlobar lymph node, Hilar lymph nodes, Lobe-specific mediastinal lymph nodes and Lobe non-specific mediastinal lymph nodes. Skipping mediastinal metastasis is defined as the metastasis of lobe nonspecific mediastinal lymph nodes, and it is confirmed pathologically by the absence of lobe specific mediastinal lymph node metastasis. The concept of lobe specific mediastinal lymph node is based on the lobe specificity of the lymphatic spread, and the characteristic lymph nodal metastasis patterns could be derived from different primary tumor locations [11, 12]. Surgeons can design an accurate strategy for lymph node dissection according to the regulation of regional lymph node metastasis.
However, each patient exhibits different clinical and pathological characteristics. Several studies have demonstrated that the incidence of lymph node metastasis differs according to individual clinical parameters and histologic components within the tumor [1317]. This patient heterogeneity finally affects the pattern of regional lymph node metastasis in early stage lung cancer.
The goal of this study was to identify the clinicopathologic characteristics that could predict the differences in metastasis among the various regional lymph nodes and to discuss the patterns for patients intraoperatively diagnosed with stage-I NSCLC. These clinicopathologic predictors will probably provide surgeons with useful information to select the appropriate lymph node dissections, especially for early stage patients.

Methods

Patient selection

A total of 595 patients who consecutively underwent surgical resection for primary lung cancer at our hospital from January 2015 to December 2017 were reviewed retrospectively. The records of patients intraoperatively diagnosed with stage-I NSCLC who underwent lobectomy or segmentectomy with complete lymph node dissection as per the nomenclature were selected for this study. All patients met the criteria for stage-I NSCLC based on the new International Staging System for NSCLC (National Comprehensive Cancer Network (NCCN) Guidelines Version 3.2014: Staging Non-Small Cell Lung Cancer) [12]. We excluded patients who exhibited any one of the following conditions: 1) preoperative tumor size > 4 cm and lymph node > 1 cm at the largest diameter on CT imaging or evidence of distant metastasis; 2) preoperative chemotherapy or radiotherapy; 3) previous or coexistent tuberculosis or malignant disease; 4) complete lymph node dissection that did not meet the current standards (i.e., all lymph node stations, including right-hand stations 2–4 and 7–9 and left-hand stations 2–9); 5) synchronous lung cancers, or 8) intraoperative frozen rapid pathological results depicting tumor size > 4 cm in the largest diameter.
Patients were preoperatively assessed with chest X-ray, chest and upper abdominal CT scan, brain magnetic resonance imaging, and bone scintigraphy. CT scan was used for preoperative N-staging. The approach for primary lung cancer resection was video-assisted thoracic surgery.
Tissue specimens contained pulmonary nodules and lymph nodes. Pulmonary nodules were analyzed using rapid frozen section in the pathology department of our medical center. The remaining nodules and lymph nodes were fixed using 10% formalin, and conventional formalin-fixed, paraffin-embedded pathological tests were performed.

Statistical analysis

The baseline patient characteristics were summarized in percent for categorical variables. The significance of associations with the outcome of lymph nodal metastases was first evaluated using a univariate logistic analysis (P < 0.20). These significant variables were further analyzed by multivariable analysis as independent predictors for lymph node metastasis (P < 0.05). Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated. Statistical analyses were performed using STATA software, release 13.

Results

Patient characteristics

A total of 595 patients intraoperatively diagnosed with stage-I NSCLC were included in this study. Table 1 displays the patient demographics and clinical characteristics. The mean age was 60 years (range 25–87 years). Among the patients, 304 (51.1%) patients had a maximum tumor diameter of 1.6 cm and 284 (47.7%) had a diameter of > 1.6 cm. The tumor originated in the right upper lobe in 181 patients (30.4%), right middle lobe in 28 (4.7%), right lower lobe in 84 (14.1%), left upper lobe in 135 (22.7%), left lower lobe in 87 (14.6%), ipsilateral mixed lobes in 48 (8.1%), and bilateral mixed lobes in 26 (4.4%). Histologically, the tumors in 442 patients (74.3%) were identified as adenocarcinoma, in 62 (10.4%) as squamous cell carcinoma, in 73 (12.3%) as in situ adenocarcinoma, and in 16 (2.7%) as others. The tumor differentiation included stage-I (125 patients, 21.0%), I–II (82 patients, 13.8%), II (139 patients, 23.4%), II–III (137 patients, 23.0%), and III (61 patients, 10.3%). Pulmonary membrane invasion was present in 58 patients (9.7%), bronchial mucosa and cartilage invasion in 54 (9.1%), vascular invasion in 44 (7.4%), and nerve invasion in 13 (2.2%). The number of patients with CEA ≤ 2.21 ng/mL was 253 (42.5%) and > 2.21 ng/mL was 254 (42.7%); albumin ≤43.1 g/L was 289 (48.6%) and > 43.1 g/L was 288 (48.4%).
Table 1
Patient demographics and clinical characteristics (n = 595)
Characteristics
Value
Age (years)
Median (Interquartile range)
60 (25–87)
  ≤ 60
301 (50.6%)
  > 60
294 (49.4%)
Sex
 Female
304 (51.1%)
 Male
291 (48.9%)
Maximum diameter of tumor
  ≤ 1.6 cm
304 (51.1%)
  > 1.6 cm
284 (47.7%)
 Missing
7 (1.2%)
Position
 Right Upper Lobe
181 (30.4%)
 Right Middle Lobe
28 (4.7%)
 Right Lower Lobe
84 (14.1%)
 Left Upper Lobe
135 (22.7%)
 Left Lower Lobe
87 (14.6%)
 Ipsilateral Mixed lobes
48 (8.1%)
 Bilateral Mixed lobes
26 (4.4%)
 Missing
6 (1.0%)
Pathological type
 Adenocarcinoma
442 (74.3%)
 Squamous cell carcinoma
62 (10.4%)
 Adenocarcinoma in situ
73 (12.3%)
 Others
16 (2.7%)
 adenosquamous carcinoma
4
 large cell neuroendocrine lung cancer
3
 metastatic colorectal cancer
1
 carcinoid
5
 sclerosing pneumocytoma
1
 lymphlepithelioma
1
 metastatic papillary thyroid cancer
1
 Missing
2 (0.35%)
Tumor differentiation
 No
28 (4.7%)
 I
125 (21.0%)
 I-II
82 (13.8%)
 II
139 (23.4%)
 II-III
137 (23.0%)
 III
61 (10.3%)
 Missing
23 (3.9%)
Pathological morphology
 No
210 (35.3%)
 lepidic
37 (6.2%)
 Acinar
178 (29.9%)
 Micropapillary
4 (0.7%)
 Papillary
85 (14.3%)
 solid
53 (8.9%)
 Missing
28 (4.7%)
Pulmonary membrane invasion
 No
431 (72.4%)
 Yes
58 (9.7%)
 Missing
106 (17.8%)
Bronchial mucosa and cartilage invasion
 No
540 (90.8%)
 Yes
54 (9.1%)
 Missing
1 (0.2%)
Vascular invasion
 No
548 (92.1%)
 Yes
44 (7.4%)
 Missing
3 (0.5%)
Nerve invasion
 No
581 (97.6%)
 Yes
13 (2.2%)
 Missing
1 (0.2%)
CEA
  ≤ 2.21 ng/ml
253 (42.5%)
  > 2.21 ng/ml
254 (42.7%)
 Missing
88 (14.8%)
Albumin
  ≤ 43.1 g/l
289 (48.6%)
  > 43.1 g/l
288 (48.4%)
 Missing
18 (3.0%)

Association of Individual clinicopathologic characteristics with metastasis of different regional lymph nodes

For the interlobar lymph node, univariate analysis showed that sex (OR = 1.95, 95% CI 0.88–4.30; P = 0.098, male patients 9.0% and female patients 4.8%), maximum diameter of the tumor (OR = 2.75, 95% CI 1.19–6.36; P = 0.018, > 1.6 cm 10.0%, ≤1.6 cm 3.9%), position (P < 0.0001, right lower lobe 26.2%, left lower lobe 9.0%, and bilateral mixed lobes 11.8% were higher than the other lobes), pulmonary membrane invasion (OR = 2.88, 95% CI 0.98–8.47; P = 0.055, present 12.5% and absent 4.7%), bronchial mucosa and cartilage invasion (OR = 2.81, 95% CI 1.07–7.40; P = 0.036, present 15.4% and absent 6.1%), vascular invasion (OR = 2.23, 95% CI 0.72–6.88; P = 0.164, present 13.3% and absent 6.5%), CEA (OR = 4.61, 95% CI 1.53–13.91; P = 0.007, > 2.21 ng/mL 9.9% and ≤ 2.21 ng/mL 2.3%), and albumin (OR = 0.27, 95% CI 0.11–0.64; P = 0.003, ≤43.1 g/L 11.3% and > 43.1 g/L 3.3%) were the 8 significant risk factors associated with metastasis (Table 2).
Table 2
Univariate and multivariate logistic regression predictors of interlobar lymph node metastasis
Independents Variables
Univariate Predictors
Multivariate Predictors
N Metastasis/N total
Odds Ratio (95% CI), P-value
B
Odds Ratio (95% CI), P-value
Age (years)
 ≤60
19/216 (8.8%)
Reference
  
 > 60
10/202 (5.0%)
0.54 (0.25–1.19), 0.540
  
Sex
 Female
10/207 (4.8%)
Reference
  
 Male
19/211 (9.0%)
1.95 (0.88–4.30), 0.098*
  
Maximum diameter of tumor
 ≤1.6 cm
8/205 (3.9%)
Reference
  
 > 1.6 cm
21/209 (10.0%)
2.75 (1.19–6.36), 0.018*
  
Position
 
< 0.0001*
  
 Right Upper Lobe
3/121 (2.5%)
Reference
  
 Right Middle Lobe
0/22 (0.0%)
0.00 (0.00-), 0.998
  
 Right Lower Lobe
16/61 (26.2%)
13.99 (3.89–50.30), < 0.0001*
  
 Left Upper Lobe
1/93 (1.1%)
0.43 (0.04–4.18), 0.465
  
 Left Lower Lobe
6/67 (9.0%)
3.87 (0.94–16.01), 0.062*
  
 Ipsilateral Mixed lobes
1/35 (2.9%)
1.16 (0.12–11.48), 0.901
  
 Bilateral Mixed lobes
2/17 (11.8%)
5.24 (0.81–33.96), 0.082*
  
Pathological type
 Adenocarcinoma
25/319 (7.8%)
Reference
  
 Others
4/98 (4.1%)
0.50 (0.17–1.48), 0.209
  
Tumor differentiation
 No
0/102 (0.0%)
Reference
  
 Yes
29/302 (9.6%)
171,607,233.80 (0.00-), 0.996
  
Pathological morphology
 No
8/140 (5.7%)
Reference
  
 Yes
21/262 (8.0%)
1.44 (0.62–3.34), 0.398
  
Pulmonary membrane invasion
 No
14/296 (4.7%)
Reference
  
 Yes
5/40 (12.5%)
2.88 (0.98–8.47), 0.055*
  
Bronchial mucosa and cartilage invasion
 No
23/379 (6.1%)
Reference
  
 Yes
6/39 (15.4%)
2.81 (1.07–7.40), 0.036*
  
Vascular invasion
 No
25/387 (6.5%)
Reference
  
 Yes
4/30 (13.3%)
2.23 (0.72–6.88), 0.164*
  
Nerve invasion
 No
28/412 (6.8%)
Reference
  
 Yes
1/6 (16.7%)
2.74 (0.31–24.29), 0.365
  
CEA
 ≤2.21 ng/ml
4/172 (2.3%)
Reference
  
 > 2.21 ng/ml
18/182 (9.9%)
4.61 (1.53–13.91), 0.007*
  
Albumin
 ≤43.1 g/l
22/195 (11.3%)
Reference
  
 > 43.1 g/l
7/212 (3.3%)
0.27 (0.11–0.64), 0.003*
  
*Only variables with P value less than 0.20 were included in the multivariate analysis
In the case of hilar lymph node, univariate analysis exposed that sex (OR = 1.83, 95% CI 1.06–3.16; P = 0.029, male patients 16.4% and female patients 9.7%), maximum tumor diameter (OR = 5.42, 95% CI 2.68–10.97; P < 0.0001, > 1.6 cm 19.9% and ≤ 1.6 cm 4.4%), position (P = 0.122, right lower lobe 19.1%, right middle lobe 25.0%, and ipsilateral mixed lobes 21.2% were higher than the other lobes), tumor differentiation (OR = 6.36, 95% CI 1.95–20.74; P = 0.002, present 16.3% and absent 3.0%), pulmonary membrane invasion (OR = 3.20, 95% CI 1.58–6.47; P = 0.001, present 25.5% and absent 9.6%), bronchial mucosa and cartilage invasion (OR = 5.57, 95% CI 2.94–10.56; P < 0.0001, present 38.5% and absent 10.1%), vascular invasion (OR = 7.68, 95% CI 3.86–15.26; P < 0.0001, present 46.3% and absent 10.1%), nerve invasion (OR = 5.90, 95% CI 1.75–19.95; P = 0.004, present 45.5% and absent 12.4%), CEA (OR = 9.66, 95% CI 3.74–24.90; P < 0.0001, > 2.21 ng/mL 20.1% and ≤ 2.21 ng/mL 2.5%), and albumin (OR = 0.27, 95% CI 0.11–0.64; P = 0.003, ≤43.1 g/L 18.2% and > 43.1 g/L 7.0%) were the 10 significant risk factors associated with metastasis (Table 3).
Table 3
Univariate and multivariate logistic regression predictors of hilar lymph node metastasis
Independents Variables
Univariate Predictors
Multivariate Predictors
N Metastasis/N total
Odds Ratio (95% CI), P-value
B
Odds Ratio (95% CI), P-value
Age (years)
 ≤ 60
31/243 (12.8%)
Reference
  
 >  60
33/245 (13.5%)
1.07 (0.63–1.80), 0.816
  
Sex
 Female
23/238 (9.7%)
Reference
  
 Male
41/250 (16.4%)
1.83 (1.06–3.16), 0.029*
  
Maximum diameter of tumor
 ≤1.6 cm
10/228 (4.4%)
Reference
  
 > 1.6 cm
51/256 (19.9%)
5.42 (2.68–10.97), < 0.0001*
  
Position
 
0.122*
  
 Right Upper Lobe
15/157 (9.6%)
Reference
  
 Right Middle Lobe
5/20 (25.0%)
3.16 (1.01–9.90), 0.049*
  
 Right Lower Lobe
13/68 (19.1%)
2.24 (1.00–5.01), 0.050*
  
 Left Upper Lobe
16/110 (14.5%)
1.61 (0.76–3.42), 0.213
  
 Left Lower Lobe
6/80 (7.5%)
0.77 (0.29–2.06), 0.600
  
 Ipsilateral Mixed lobes
7/33 (21.2%)
2.55 (0.95–6.86), 0.064*
  
 Bilateral Mixed lobes
2/16 (12.5%)
1.35 (0.28–6.53), 0.707
  
Pathological type
 Adenocarcinoma
51/370 (13.8%)
Reference
  
 Others
13/118 (11.0%)
0.77 (0.41–1.48), 0.439
  
Tumor differentiation
 No
3/101 (3.0%)
Reference
  
 Yes
60/368 (16.3%)
6.36 (1.95–20.74), 0.002*
  
Pathological morphology
 No
21/167 (12.6%)
Reference
  
 Yes
42/306 (13.7%)
1.11 (0.63–1.94), 0.725
  
Pulmonary membrane invasion
 No
33/342 (9.6%)
Reference
  
 Yes
14/55 (25.5%)
3.20 (1.58–6.47), 0.001*
  
Bronchial mucosa and cartilage invasion
 No
44/436 (10.1%)
Reference
  
 Yes
20/52 (38.5%)
5.57 (2.94–10.56), < 0.0001*
1.13
3.11 (1.19–8.13), 0.021#
Vascular invasion
 No
45/445 (10.1%)
Reference
  
 Yes
19/41 (46.3%)
7.68 (3.86–15.26), < 0.0001*
1.09
2.98 (1.14–7.81), 0.026#
Nerve invasion
 No
59/477 (12.4%)
Reference
  
 Yes
5/11 (45.5%)
5.90 (1.75–19.95), 0.004*
  
CEA
 ≤2.21 ng/ml
5/197 (2.5%)
Reference
  
 > 2.21 ng/ml
44/219 (20.1%)
9.66 (3.74–24.90), < 0.0001*
2.14
8.49 (2.49–28.97), 0.001#
Albumin
 ≤43.1 g/l
45/247 (18.2%)
Reference
  
 > 43.1 g/l
16/227 (7.0%)
0.27 (0.11–0.64), 0.003*
  
*Only variables with P value less than 0.20 were included in the multivariate analysis. # P < 0.05 Sum might not always be in total because of missing data
For the lobe specific mediastinal lymph node, univariate analysis established that sex (OR = 1.97, 95% CI 1.08–3.59; P = 0.028, male patients 11.1% and female patients 6.0%), maximum tumor diameter (OR = 4.76, 95% CI 2.33–9.74; P < 0.0001, > 1.6 cm 14% and ≤ 1.6 cm 3.3%), position (P = 0.096, right lower lobe 16.7% and right middle lobe 14.3% were higher than the other lobes), tumor differentiation (OR = 9.93, 95% CI 2.38–41.37; P = 0.002, present 11.6% and absent 1.3%), pulmonary membrane invasion (OR = 3.95, 95% CI 1.87–8.34; P < 0.0001, present 21.1% and absent 6.3%), bronchial mucosa and cartilage invasion (OR = 4.84, 95% CI 2.41–9.71; P < 0.0001, present 25.9% and absent 6.7%), vascular invasion (OR = 7.49, 95% CI 3.68–15.26; P < 0.0001, present 34.1% and absent 6.5%), nerve invasion (OR = 3.75, 95% CI 0.98–14.33; P = 0.053, present 25.0% and absent 8.2%), CEA (OR = 6.53, 95% CI 2.69–15.82; P < 0.0001, > 2.21 ng/mL 13.8% and ≤ 2.21 ng/mL 2.4%), and albumin (OR = 0.46, 95% CI 0.25–0.85; P = 0.013, ≤43.1 g/L 11.5% and > 43.1 g/L 5.6%) were the 10 significant risk factors associated with metastasis (Table 4).
Table 4
Univariate and Multivariate Logistic Regression Predictors of Lobe specific Mediastinal lymph Node Metastasis
Independents Variables
Univariate Predictors
Multivariate Predictors
N Metastasis/N total
Odds Ratio (95% CI), P-value
B
Odds Ratio (95% CI), P-value
Age (years)
 ≤60
25/298 (8.4%)
Reference
  
 > 60
25/291 (8.6%)
1.03 (0.58–1.83), 0.930
  
Sex
 Female
18/301 (6.0%)
Reference
  
 Male
32/288 (11.1%)
1.97 (1.08–3.59), 0.028*
  
Maximum diameter of tumor
 ≤1.6 cm
10/303 (3.3%)
Reference
  
 > 1.6 cm
39/279 (14.0%)
4.76 (2.33–9.74), < 0.0001*
1.16
3.18 (1.15–8.78), 0.026#
Position
0.096*
 
0.019#
 Right Upper Lobe
9/181 (5.0%)
Reference
 
 Right Middle Lobe
4/28 (14.3%)
3.19 (0.91–11.15), 0.070*
1.78
5.92 (0.93–37.66), 0.060
 Right Lower Lobe
14/84 (16.7%)
3.82 (1.58–9.24), 0.003*
2.42
11.29 (2.50–51.04), 0.002#
 Left Upper Lobe
10/135 (7.4%)
1.53 (0.60–3.87), 0.371
0.06
1.07 (0.22–5.07), 0.937
 Left Lower Lobe
7/87 (8.0%)
1.67 (0.60–4.65), 0.324
1.21
3.35 (0.78–14.38),0.103
 Ipsilateral Mixed lobes
4/48 (8.3%)
1.74 (0.51–5.91), 0.376
1.93
6.89 (1.16–40.83),0.034#
 Bilateral Mixed lobes
2/26 (7.7%)
1.59 (0.33–7.81), 0.566
2.54
12.69 (1.65–97.51),0.015#
Pathological type
 Adenocarcinoma
41/440 (9.3%)
Reference
  
 Others
9/147 (6.1%)
0.64 (0.30–1.34), 0.233
  
Tumor differentiation
 No
2/153 (1.3%)
Reference
  
 Yes
48/413 (11.6%)
9.93 (2.38–41.37), 0.002*
  
Pathological morphology
 No
16/209 (7.7%)
Reference
  
 Yes
33/356 (9.3%)
1.23 (0.66–2.30), 0.511
  
Pulmonary membrane invasion
 No
27/427 (6.3%)
Reference
  
 Yes
12/57 (21.1%)
3.95 (1.87–8.34), < 0.0001*
1.53
4.60 (1.60–13.23),0.005#
Bronchial mucosa and cartilage invasion
 No
36/534 (6.7%)
Reference
  
 Yes
14/54 (25.9%)
4.84 (2.41–9.71), < 0.0001*
  
Vascular invasion
 No
35/542 (6.5%)
Reference
  
 Yes
15/44 (34.1%)
7.49 (3.68–15.26), < 0.0001*
1.35
3.85 (1.26–11.78), 0.018#
Nerve invasion
 No
47/576 (8.2%)
Reference
  
 Yes
3/12 (25.0%)
3.75 (0.98–14.33), 0.053*
  
CEA
 ≤2.21 ng/ml
6/250 (2.4%)
Reference
  
 > 2.21 ng/ml
35/253 (13.8%)
6.53 (2.69–15.82), < 0.0001*
1.79
6.01 (1.86–19.44), 0.003#
Albumin
 ≤43.1 g/l
33/287 (11.5%)
Reference
  
 > 43.1 g/l
16/286 (5.6%)
0.46 (0.25–0.85), 0.013*
  
*Only variables with P value less than 0.20 were included in the multivariate analysis. # P < 0.05 Sum might not always be in total because of missing data
For the lobe nonspecific mediastinal lymph node, univariate analysis indicated that tumor differentiation (OR = 2.68, 95% CI 0.79–9.11; P = 0.115, present 5.1% and absent 2.0%), bronchial mucosa and cartilage invasion (OR = 3.58, 95% CI 1.36–9.45; P = 0.010, present 11.1% and absent 3.4%), vascular invasion (OR = 7.31, 95% CI 2.93–18.21; P < 0.0001, present 18.2% and absent 3.0%), and nerve invasion (OR = 8.81, 95% CI 2.22–34.93; P = 0.002, present 25.0% and absent 3.6%) were the 4 significant risk factors associated with metastasis (Table 5).
Table 5
Univariate and multivariate logistic regression predictors of lobe non-specific mediastinal lymph node metastasis
Independents Variables
Univariate Predictors
Multivariate Predictors
N Metastasis/N total
Odds Ratio (95% CI), P-value
B
Odds Ratio (95% CI), P-value
Age (years)
 ≤60
15/298 (5.0%)
Reference
  
 > 60
9/291 (3.1%)
0.60 (0.26–1.40), 0.238
  
Sex
 Female
14/301 (4.7%)
Reference
  
 Male
10/288 (3.5%)
0.74 (0.32–1.69), 0.471
  
Maximum diameter of tumor
 ≤1.6 cm
9/303 (3.0%)
Reference
  
 > 1.6 cm
14/279 (5.0%)
1.73 (0.74–4.05), 0.210
  
Position
 
0.535
  
 Right Upper Lobe
5/181 (2.8%)
Reference
  
 Right Middle Lobe
0/28 (0.0%)
0.00 (0.00,) 0.998
  
 Right Lower Lobe
7/84 (8.3%)
3.20 (0.99–10.40), 0.053
  
 Left Upper Lobe
4/135 (3.0%)
1.08 (0.28–4.08), 0.916
  
 Left Lower Lobe
4/87 (4.6%)
1.70 (0.44–6.48), 0.440
  
 Ipsilateral Mixed lobes
3/48 (6.3%)
2.35 (0.54–10.19), 0.255
  
 Bilateral Mixed lobes
1/26 (3.8%)
1.41 (0.16–12.55), 0.759
  
Pathological type
 Adenocarcinoma
17/440 (3.9%)
Reference
  
 Others
7/147 (4.8%)
1.24 (0.51–3.06), 0.635
  
Tumor differentiation
 No
3/153 (2.0%)
Reference
  
 Yes
21/413 (5.1%)
2.68 (0.79–9.11), 0.115*
  
Pathological morphology
 No
8/209 (3.8%)
Reference
  
 Yes
16/356 (4.5%)
1.18 (0.50–2.81), 0.705
  
Pulmonary membrane invasion
 No
15/427 (3.5%)
Reference
  
 Yes
4/57 (7.0%)
2.07 (0.66–6.48), 0.210
  
Bronchial mucosa and cartilage invasion
 No
18/534 (3.4%)
Reference
  
 Yes
6/54 (11.1%)
3.58 (1.36–9.45), 0.010*
  
Vascular invasion
 No
16/542 (3.0%)
Reference
  
 Yes
8/44 (18.2%)
7.31 (2.93–18.21), < 0.0001*
1.59
4.89 (1.78–13.40), 0.002#
Nerve invasion
 No
21/576 (3.6%)
Reference
  
 Yes
3/12 (25.0%)
8.81 (2.22–34.93), 0.002*
1.55
4.73 (1.05–21.35), 0.043#
CEA
 ≤2.21 ng/ml
8/250 (3.2%)
Reference
  
 > 2.21 ng/ml
14/253 (5.5%)
1.77 (0.73–4.30), 0.206
  
Albumin
 ≤43.1 g/l
12/287 (4..2%)
Reference
  
 > 43.1 g/l
11/286 (3.8%)
0.92 (0.40–2.11), 0.838
  
*Only variables with P value less than 0.20 were included in the multivariate analysis. # P < 0.05 Sum might not always be in total because of missing data
As for skipping mediastinal lymph node, univariate analysis disclosed that age (OR = 0.38, 95% CI 0.10–1.44; P = 0.153, ≤60 2.7% and > 60 0%), sex (OR = 0.39, 95% CI 0.10–1.47; P = 0.162, female patients 2.7% and male patients 1.0%), nerve invasion (OR = 12.60, 95% CI 2.41–65.93; P = 0.003, present 16.7% and absent 1.6%), and albumin (OR = 0.34, 95% CI 0.19–0.62; P < 0.0001, > 43.1 g/L 2.8% and ≤ 43.1 g/L 1.0%) were the 4 significant risk factors associated with metastasis (Table 6).
Table 6
Univariate and Multivariate Logistic Regression Predictors of Skipping Mediastinal lymph Node Metastasis
Independents Variables
Univariate Predictors
Multivariate Predictors
N Metastasis/N total
Odds Ratio (95% CI), P-value
B
Odds Ratio (95% CI), P-value
Age (years)
 ≤60
8/298 (2.7%)
Reference
 
 > 60
3/291 (0%)
0.38 (0.10–1.44), 0.153*
Sex
 Female
8/301 (2.7%)
Reference
 
 Male
3/288 (1.0%)
0.39 (0.10–1.47), 0.162*
Maximum diameter of tumor
 ≤1.6 cm
6/303 (2.0%)
Reference
 
 > 1.6 cm
4/279 (1.4%)
0.72 (0.20–2.58), 0.614
Position
0.961
 Right Upper Lobe
4/181 (2.2%)
Reference
 Right Middle Lobe
0/28 (0.0%)
0.00 (0.00,), 0.998
 Right Lower Lobe
3/84 (3.6%)
1.64 (0.36–7.49), 0.524
 Left Upper Lobe
2/135 (1.5%)
0.67 (0.12–3.69), 0.641
 Left Lower Lobe
1/87 (1.1%)
0.52 (0.06–4.67), 0.555
 Ipsilateral Mixed lobes
1/48 (2.1%)
0.94 (0.10–8.62), 0.957
 Bilateral Mixed lobes
0/26 (0.0%)
0.00 (0.00,), 0.998
Pathological type
 Adenocarcinoma
7/440 (1.6%)
Reference
 
 Others
4/147 (2.75)
1.73 (0.50–6.00), 0.387
Tumor differentiation
 No
2/153 (1.3%)
Reference
 
 Yes
9/413 (2.2%)
1.68 (0.36–7.87), 0.509
Pathological morphology
 No
4/209 (1.9%)
Reference
 
 Yes
7/356 (2.0%)
1.03 (0.30–3.55), 0.965
Pulmonary membrane invasion
 No
8/427 (1.9%)
Reference
 
 Yes
2/57 (3.5%)
1.91 (0.39–9.20), 0.423
Bronchial mucosa and cartilage invasion
 No
10/534 (1.9%)
Reference
 
 Yes
1/54 (1.9%)
0.99 (0.12–7.87), 0.991
Vascular invasion
 No
10/542 (1.8%)
Reference
 
 Yes
1/44 (2.3%)
1.24 (0.16–9.89), 0.841
Nerve invasion
 No
9/576 (1.6%)
Reference
 
 Yes
2/12 (16.7%)
12.60 (2.41–65.93), 0.003*
3.37
29.11 (3.81–222.61), 0.001#
CEA
 ≤2.21 ng/ml
6/250 (2.4%)
Reference
 
 > 2.21 ng/ml
5/253 (2.0%)
0.82 (0.25–2.72), 0.746
Albumin
 ≤43.1 g/l
3/287 (1.0%)
Reference
 
 > 43.1 g/l
8/286 (2.8%)
0.34 (0.19–0.62), < 0.0001*
1.63
5.09 (0.99–26.20), 0.051#
*Only variables with P value less than 0.20 were included in the multivariate analysis. # P < 0.05 Sum might not always be in total because of missing data

Multivariable analysis of clinicopathologic characteristics associated with metastasis of different regional lymph nodes

For the interlobar lymph node, multivariate analysis of the 8 risk factors obtained from univariate analysis suggested that none of them were significant predictors of interlobar lymph node metastasis (Table 2).
For the hilar lymph node, multivariate analysis of the 10 risk factors acquired from univariate analysis showed that only bronchial mucosa and cartilage invasion (absent vs. present, OR = 3.11, 95% CI 1.19–8.13; P = 0.021), vascular invasion (absent vs. present, OR = 2.98, 95% CI 1.14–7.81; P = 0.026), and CEA (≤2.21 ng/mL vs. > 2.21 ng/mL, OR = 8.49, 95% CI 2.49–28.97; P = 0.001) were the 3 independent predictors associated with metastasis (Table 3).
For the lobe specific mediastinal lymph node, multivariate analysis of the 10 risk factors resulting from univariate analysis indicated that only the maximum diameter of the tumor (≤1.6 cm vs. > 1.6 cm, OR = 3.18, 95% CI 1.15–8.87; P = 0.026), position (P = 0.019), pulmonary membrane invasion (absent vs. present, OR = 4.60, 95% CI 1.60–13.23; P = 0.005), vascular invasion (absent vs. present, OR = 3.85, 95% CI 1.26–11.78; P = 0.018), and CEA (≤2.21 ng/mL vs. > 2.21 ng/mL, OR = 6.01, 95% CI 1.86–19.44; P = 0.003) were the 5 independent predictors associated with metastasis (Table 4).
For the lobe nonspecific mediastinal lymph node, multivariate analysis of the 4 risk factors obtained from univariate analysis revealed that only vascular (absent vs. present, OR = 4.89, 95% CI 1.78–13.40; P = 0.002) and nerve invasions (absent vs. present, OR = 4.73, 95% CI 1.05–21.35; P = 0.043) were the 2 independent predictors associated with the presence of metastasis (Table 5).
For the skipping mediastinal lymph node, multivariate analysis of the 4 risk factors derived from univariate analysis established that only nerve invasion (absent vs. present, OR = 29.11, 95% CI 3.81–222.61; P = 0.001) and albumin (≤43.1 g/L vs. > 43.1 g/L, OR = 5.09, 95% CI 0.99–26.20; P = 0.051) were the 2 independent predictors associated with the presence of metastasis (Table 6).

Discussion

Evaluation of regional lymph node metastasis is important for surgeons to determine the treatment and prognosis [18]. Accordingly, regional lymph node maps have been created to standardize the assessment of metastasis. In these maps, lymph nodes are labeled using a system of numerical levels and assigned names based on their anatomical location [19, 20]. The International Association for the Study of Lung Cancer (IASLC) lymph node map is employed in the eighth edition of the TNM staging system [21]. According to the sequence of the lymph node map, lung cancer cells initially spread to the ipsilateral interlobar lymph nodes, then to the hilar lymph nodes, and finally to the mediastinal lymph nodes.
The concept of lobe specific mediastinal lymph nodes is based on the lobe specificity of the lymphatic spread [22]. In literature, lobe specific MLNs have been defined as 2R, 3, and 4R for the right upper lobe; 3, 7, and 8 for the right lower lobe; 4 L, 5, and 7 for the left upper lobe; and 4 L, 7, and 8 for the left lower lobe. However, Kotoulasa et al. and Shapiro et al. proposed a simpler pattern. Right upper lobe tumors mainly metastasize to 4R, right middle lobe to 4R and 7, right lower lobe to 7, left upper lobe to 5, and left lower lobe to 7 and 9 [11, 12]. An analysis of the recent literature led to our definitions of lobe specific lymph nodes: 2, 3, and 4 for the right upper lobe; 4 and 7 for the right middle lobe; 7 and 8 for the right lower lobe; 5 and 7 for the left upper lobe; and 7, 8, and 9 for the left lower lobe.
A complete mediastinal lymph node dissection which removes all ipsilateral mediastinal lymph nodes [23], can provide more accurate pathological staging and improved clinical outcomes for some patients. This approach is considered a standard surgical treatment for patients diagnosed preoperatively with mediastinal lymph node metastases. However, complete mediastinal lymph node dissection is not considered a routine surgical treatment for patients with stage-I NSCLC because of the increased incidence of postoperative complications including increase in blood loss, median operative time, total chest-tube drainage and occurrence rate of chylothorax. The rapid pathological results would help surgeons to make decisions about which patterns should be performed; wedge resection, segmentectomy, or lobectomy. However, surgeons do not know which pattern should be chosen for lymph node dissection and we need some guidance from clinical research. Mark Shapiro et al. further demonstrated the importance of lobe specific MLN regarded as sentinel lymph nodes in mediastinal position in the surgical treatment of early stage lung cancer [12]. Each patient exhibits different clinicopathologic characteristics that determine the risk for regional lymph node metastasis in early stage lung cancer. We attempted to identify the risk factors to predict lymph node metastasis and allow surgeons to make appropriate decisions on the extent of the dissection. For some early patients, surgeon can remove regional lymph nodes such as lobe specific MLN that are most likely to contain metastases and avoid unnecessary systemic complete lymph nodes dissection in order to accelerate patients’ postoperative recovery.
First, we used univariate analysis to ascertain the associations between clinicopathologic factors and regional lymph node metastasis. The results disclosed that sex (male patients), maximum diameter of the tumor (> 1.6 cm), position (right lower lobe, left lower lobe, and bilateral mixed lobes), pulmonary membrane invasion, bronchial mucosa and cartilage invasion, vascular invasion, CEA (> 2.21 ng/mL), and albumin (≤43.1 g/L) were the 8 significant risk factors associated with the presence of metastatic interlobar lymph nodes.
Sex (male patients), maximum diameter of the tumor (> 1.6 cm), position (right lower lobe, right middle lobe, and ipsilateral mixed lobes), tumor differentiation, pulmonary membrane invasion, bronchial mucosa and cartilage invasion, vascular invasion, nerve invasion, CEA (> 2.21 ng/mL), and albumin (≤43.1 g/L) were the 10 significant risk factors associated with the presence of metastatic hilar lymph nodes.
Sex (male patients), maximum diameter of the tumor (> 1.6 cm), position (right lower lobe, and right middle lobe), tumor differentiation, pulmonary membrane invasion, bronchial mucosa and cartilage invasion, vascular invasion, nerve invasion, CEA (> 2.21 ng/mL), and albumin (≤43.1 g/L, 11.5%) were the 10 significant risk factors associated with the presence of metastatic lobe specific mediastinal lymph nodes.
Tumor differentiation, bronchial mucosa and cartilage invasion, vascular invasion, and nerve invasion were the 4 significant risk factors associated with the presence of metastatic lobe nonspecific mediastinal lymph nodes.
Age (≤60), sex (female patients), nerve invasion, and albumin (> 43.1 g/L) were the 4 significant risk factors associated with the presence of metastatic skipping mediastinal lymph nodes.
Furthermore, multivariate analysis of these factors identified using univariate analysis suggested that all the risk factors were not significant predictors of interlobar lymph node metastasis.
Only bronchial mucosa and cartilage invasion, vascular invasion, and CEA (> 2.21 ng/mL) were the three independent predictors associated with the presence of metastatic hilar lymph nodes. Therefore, when patients are suspected of having bronchial mucosa and cartilage invasion, vascular invasion, and CEA (> 2.21 ng/mL), hilar lymph node dissection should probably be performed.
Only maximum diameter of the tumor (> 1.6 cm), position (right lower lobe, ipsilateral mixed lobes, and bilateral mixed lobes), pulmonary membrane invasion, vascular invasion, and CEA (> 2.21 ng/mL) were the 5 independent predictors associated with the presence of metastatic lobe specific mediastinal lymph nodes. Hence, when patients are suspected of pulmonary membrane invasion, vascular invasion, CEA (> 2.21 ng/mL), and tumor (> 1.6 cm) in the right lower lobe or mixed lobes, lobe specific lymph node dissection should probably be performed.
Only nerve and vascular invasions were the two independent predictors associated with the presence of metastatic lobe nonspecific mediastinal lymph nodes. Hence, when patients are suspected of nerve and vascular invasions, complete mediastinal lymph node dissection should probably be performed.
Only nerve invasion and albumin (> 43.1 g/L) were the two independent predictors associated with the presence of metastatic skipping mediastinal lymph nodes. Therefore, when patients are suspected of nerve invasion and albumin (> 43.1 g/L), complete mediastinal lymph node dissection should probably be performed.
These results demonstrate the possibility of changes to lymph node metastasis when a tumor invades different tissues. In early-stage metastasis, the tumor invades bronchial mucosa and cartilage, pulmonary membranes, and vascular tissue only. During this stage, the CEA level (> 2.21 ng/mL) is likely to be an important predictor indicating that the tumor began to metastasize from the lymphatic system. Therefore, hilar and lobe-specific mediastinal lymph nodes, which are most likely to become the first metastatic stations, should be surgically removed. In later stages of lymph node metastasis, when the tumor begins to invade vascular and neural tissues, the albumin level (> 43.1 g/L) is likely to be an important predictor that indicates and promotes skip metastasis. When there is an increased possibility of broad mediastinal metastases, a complete mediastinal lymph-node dissection is required to ensure that all suspected metastatic lymph nodes are removed.
However, our study has some limitations. This study was conducted at a single institution with retrospective methods and demonstrated the necessity of further prospective study. Further prospective study with multicenter trial should be performed to comprehensively evaluate clinicopathologic predictors of metastasis of different regional lymph nodes in patients intraoperatively diagnosed with stage-I non-small cell lung cancer.

Conclusions

After a comprehensive analysis of results concerning the different clinicopathologic factors, we conclude that complete mediastinal lymph node dissection should probably be performed for patients suspected of nerve invasion and albumin (> 43.1 g/L) or nerve and vascular invasions; lobe specific lymph node dissection should probably be performed for patients suspected of pulmonary membrane invasion, vascular invasion, CEA (> 2.21 ng/mL), and tumor (> 1.6 cm) in the right lower lobe or mixed lobes; hilar lymph node dissection should probably be performed for patients suspected of having bronchial mucosa and cartilage invasion, vascular invasion, and CEA (> 2.21 ng/mL).

Acknowledgements

We thank Dr. Quan Zhu and Dr. Wei-Bing Wu for their constructive suggestions and comments.

Funding

This work was supported by Natural Science Foundation of Jiangsu Province (BK20151589) which provided funds for collection and analysis of clinical data.

Availability of data and materials

We presented raw data within Additional file 1.
This study was conducted in accordance with the amended Declaration of Helsinki. The approval of the Ethical Committee of Nanjing Medical University was obtained (project approval no. 2012-SRFA-161). The written informed consent from either the patients or their representatives was waived due to the retrospective nature of this study in accordance with the American Medical Association.
Not applicable

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
Anhänge

Additional file

Additional file 1: Support file containing the Age (G), cigarettes (0:negative, 1:positive), Alcohol (0:negative, 1:positive), chronic bronchitis (0:negative, 1:positive), diabetes (0:negative, 1:positive), tumor history (0:negative, 1:positive), tumor family history (0:negative, 1:positive), blood type (0:A,1:B,2:O,3:AB), Neutrophil(G), Lymphocyte(G), N/L(G), Platelet(G), Serum Albumin(G), ALP(G), Serum Globulin(G), Al/Gl ratio(G), APTT(G), PT(G), CEA(G), CYFRA211(G), NSE(G), Tumor size(G), Tumor location (0:right upper,1:right middle,2:right lower,3:left upper,4:left lower,5:Ipsilateral), Tumor location(G), Pathology (0:AdCa,1:SqCa,2:Adenocarcinoma in situ,3:other), Pathology(G),Grade (G), Pathological morphology (1:lepidic, 2:Acinar, 3:Micropapillary, 4:Papillary, 5:solid), Pathological morphology(G), Pulmonary membrane invasion (0:negative, 1:positive), Bronchial mucosa and cartilage invasion (0:negative, 1:positive), Vascular invasion (0:negative, 1:positive), Nerve invasion (0:negative, 1:positive), Lobe-specific mediastinal lymph nodes (1:metastasis 0:no metastasis),Lobe non-specific mediastinal lymph nodes (1:metastasis 0:no metastasis), skiping mediastinal lymph nodes (1:metastasis 0:no metastasis),2, 4station(1:metastasis 0:no metastasis),5, 6station(1:metastasis 0:no metastasis),7station(1:metastasis 0:no metastasis),8station(1:metastasis 0:no metastasis), 9station(1:metastasis 0:no metastasis), hilar lymph nodes (10 station)(1:metastasis 0:no metastasis), interlobe lymph nodes (11 station)(1,metastasis 0,no metastasis) described in categorical variables and Age ranges (yrs), number of cigarettes, Tumor size (cm). Neutrophil, Lymphocyte, N/L, Platelet, Serum Albumin, ALP, Serum Globulin, Al/Gl ratio, APTT, PT, CEA, CYFRA211, NSE described in continuous variables. (XLSX 173 kb)
Literatur
1.
Zurück zum Zitat De Leyn P, Dooms C, Kuzdzal J, Lardinois D, Passlick B, Rami-Porta R, et al. Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer. Eur J Cardiothorac Surg. 2014;45:787–98.CrossRef De Leyn P, Dooms C, Kuzdzal J, Lardinois D, Passlick B, Rami-Porta R, et al. Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer. Eur J Cardiothorac Surg. 2014;45:787–98.CrossRef
2.
Zurück zum Zitat Gdeedo A, Van Schil P, Corthouts B, Van Mieghem F, Van Meerbeeck J, Van Marck E. Prospective evaluation of computed tomography and mediastinoscopy in mediastinal lymph node staging. Eur Respir J. 1997;10:1547–51.CrossRef Gdeedo A, Van Schil P, Corthouts B, Van Mieghem F, Van Meerbeeck J, Van Marck E. Prospective evaluation of computed tomography and mediastinoscopy in mediastinal lymph node staging. Eur Respir J. 1997;10:1547–51.CrossRef
3.
Zurück zum Zitat Gupta NC, Graeber GM, Bishop HA. Comparative efficacy of positron emission tomography with fluorodeoxyglucose in evaluation of small (<1 cm), intermediate (1 to 3 cm), and large (>3 cm) lymph node lesions. Chest. 2000;117:773–8.CrossRef Gupta NC, Graeber GM, Bishop HA. Comparative efficacy of positron emission tomography with fluorodeoxyglucose in evaluation of small (<1 cm), intermediate (1 to 3 cm), and large (>3 cm) lymph node lesions. Chest. 2000;117:773–8.CrossRef
4.
Zurück zum Zitat Prenzel KL, Monig SP, Sinning JM, Baldus SE, Brochhagen HG, Schneider PM, et al. Lymph node size and metastatic infiltration in non-small cell lung cancer. Chest. 2003;123:463–7.CrossRef Prenzel KL, Monig SP, Sinning JM, Baldus SE, Brochhagen HG, Schneider PM, et al. Lymph node size and metastatic infiltration in non-small cell lung cancer. Chest. 2003;123:463–7.CrossRef
5.
Zurück zum Zitat Sioris T, Jarvenpaa R, Kuukasjarvi P, Helin H, Saarelainen S, Tarkka M. Comparison of computed tomography and systematic lymph node dissection in determining TNM and stage in non-small cell lung cancer. Eur J Cardiothorac Surg. 2003;23:403–8.CrossRef Sioris T, Jarvenpaa R, Kuukasjarvi P, Helin H, Saarelainen S, Tarkka M. Comparison of computed tomography and systematic lymph node dissection in determining TNM and stage in non-small cell lung cancer. Eur J Cardiothorac Surg. 2003;23:403–8.CrossRef
6.
Zurück zum Zitat Steinert HC, Hauser M, Allemann F, Engel H, Berthold T, von Schulthess GK, et al. Non-small cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling. Radiology. 1997;202:441–6.CrossRef Steinert HC, Hauser M, Allemann F, Engel H, Berthold T, von Schulthess GK, et al. Non-small cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling. Radiology. 1997;202:441–6.CrossRef
7.
Zurück zum Zitat Izbicki JR, Passlick B, Pantel K, Pichlmeier U, Hosch SB, Karg O, et al. Effectiveness of radical systematic mediastinal lymphadenectomy in patients with resectable non-small cell lung cancer: results of a prospective randomized trial. Ann Surg. 1998;227:138–44.CrossRef Izbicki JR, Passlick B, Pantel K, Pichlmeier U, Hosch SB, Karg O, et al. Effectiveness of radical systematic mediastinal lymphadenectomy in patients with resectable non-small cell lung cancer: results of a prospective randomized trial. Ann Surg. 1998;227:138–44.CrossRef
8.
Zurück zum Zitat Hermens FH, Van Engelenburg TC, Visser FJ, Thunnissen FB, Termeer R, Janssen JP. Diagnostic yield of transbronchial histology needle aspiration in patients with mediastinal lymph node enlargement. Respiration. 2003;70:631–5.CrossRef Hermens FH, Van Engelenburg TC, Visser FJ, Thunnissen FB, Termeer R, Janssen JP. Diagnostic yield of transbronchial histology needle aspiration in patients with mediastinal lymph node enlargement. Respiration. 2003;70:631–5.CrossRef
9.
Zurück zum Zitat Annema JT, Veselic M, Versteegh MI, Willems LN, Rabe KF. Mediastinal restaging: EUS-FNA offers a new perspective. Lung Cancer. 2003;42:311–8.CrossRef Annema JT, Veselic M, Versteegh MI, Willems LN, Rabe KF. Mediastinal restaging: EUS-FNA offers a new perspective. Lung Cancer. 2003;42:311–8.CrossRef
10.
Zurück zum Zitat Freixinet Gilart J, Garcia PG, de Castro FR, Suarez PR, Rodriguez NS, de Ugarte AV. Extended cervical mediastinoscopy in the staging of bronchogenic carcinoma. Ann Thorac Surg. 2000;70:1641–3.CrossRef Freixinet Gilart J, Garcia PG, de Castro FR, Suarez PR, Rodriguez NS, de Ugarte AV. Extended cervical mediastinoscopy in the staging of bronchogenic carcinoma. Ann Thorac Surg. 2000;70:1641–3.CrossRef
11.
Zurück zum Zitat Kotoulas CS, Foroulis CN, Kostikas K, Konstantinou M, Kalkandi P, Dimadi M, et al. Involvement of lymphatic metastatic spread in non-small cell lung cancer accordingly to the primary cancer location. Lung Cancer. 2004;44:183–91.CrossRef Kotoulas CS, Foroulis CN, Kostikas K, Konstantinou M, Kalkandi P, Dimadi M, et al. Involvement of lymphatic metastatic spread in non-small cell lung cancer accordingly to the primary cancer location. Lung Cancer. 2004;44:183–91.CrossRef
12.
Zurück zum Zitat Shapiro M, Kadakia S, Lim J, Breglio A, Wisnivesky JP, Kaufman A, et al. Lobe-specific mediastinal nodal dissection is sufficient during lobectomy by video-assisted thoracic surgery or thoracotomy for early-stage lung cancer. Chest. 2013;144:1615–21.CrossRef Shapiro M, Kadakia S, Lim J, Breglio A, Wisnivesky JP, Kaufman A, et al. Lobe-specific mediastinal nodal dissection is sufficient during lobectomy by video-assisted thoracic surgery or thoracotomy for early-stage lung cancer. Chest. 2013;144:1615–21.CrossRef
13.
Zurück zum Zitat Yanagawa N, Shiono S, Abiko M, Ogata SY, Sato T, Tamura G. The correlation of the International Association for the Study of Lung Cancer (IASLC)/American Thoracic Society (ATS)/European Respiratory Society (ERS) classification with prognosis and EGFR mutation in lung adenocarcinoma. Ann Thorac Surg. 2014;98:453–8.CrossRef Yanagawa N, Shiono S, Abiko M, Ogata SY, Sato T, Tamura G. The correlation of the International Association for the Study of Lung Cancer (IASLC)/American Thoracic Society (ATS)/European Respiratory Society (ERS) classification with prognosis and EGFR mutation in lung adenocarcinoma. Ann Thorac Surg. 2014;98:453–8.CrossRef
14.
Zurück zum Zitat Kadota K, Villena-Vargas J, Yoshizawa A, Motoi N, Sima CS, Riely GJ, et al. Prognostic significance of adenocarcinoma in situ, minimally invasive adenocarcinoma, and nonmucinous lepidic predominant invasive adenocarcinoma of the lung in patients with stage I disease. Am J Surg Pathol. 2014;38:448–60.CrossRef Kadota K, Villena-Vargas J, Yoshizawa A, Motoi N, Sima CS, Riely GJ, et al. Prognostic significance of adenocarcinoma in situ, minimally invasive adenocarcinoma, and nonmucinous lepidic predominant invasive adenocarcinoma of the lung in patients with stage I disease. Am J Surg Pathol. 2014;38:448–60.CrossRef
15.
Zurück zum Zitat Ito M, Miyata Y, Kushitani K, Yoshiya T, Mimae T, Ibuki Y, et al. Prediction for prognosis of resected pT1a-1bN0M0 adenocarcinoma based on tumor size and histological status: relationship of TNM and IASLC/ATS/ERS classifications. Lung Cancer. 2014;85:270–5.CrossRef Ito M, Miyata Y, Kushitani K, Yoshiya T, Mimae T, Ibuki Y, et al. Prediction for prognosis of resected pT1a-1bN0M0 adenocarcinoma based on tumor size and histological status: relationship of TNM and IASLC/ATS/ERS classifications. Lung Cancer. 2014;85:270–5.CrossRef
16.
Zurück zum Zitat Zhang J, Wu J, Tan Q, Zhu L, Gao W. Why do pathological stage IA lung adenocarcinomas vary from prognosis?: a clinicopathologic study of 176 patients with pathological stage IA lung adenocarcinoma based on the IASLC/ATS/ERS classification. J Thorac Oncol. 2013;8:1196–202.CrossRef Zhang J, Wu J, Tan Q, Zhu L, Gao W. Why do pathological stage IA lung adenocarcinomas vary from prognosis?: a clinicopathologic study of 176 patients with pathological stage IA lung adenocarcinoma based on the IASLC/ATS/ERS classification. J Thorac Oncol. 2013;8:1196–202.CrossRef
17.
Zurück zum Zitat Moon Y, Kim KS, Sung SW, Lee KY, Kim YK, Kang JH, et al. Correlation of histological components with tumor invasion in pulmonary adenocarcinoma. World J Surg Oncol. 2014;12:388.CrossRef Moon Y, Kim KS, Sung SW, Lee KY, Kim YK, Kang JH, et al. Correlation of histological components with tumor invasion in pulmonary adenocarcinoma. World J Surg Oncol. 2014;12:388.CrossRef
18.
Zurück zum Zitat Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The eighth edition AJCC Cancer staging manual: continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin. 2017;67:93–9.CrossRef Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The eighth edition AJCC Cancer staging manual: continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin. 2017;67:93–9.CrossRef
19.
Zurück zum Zitat Ishikawa S, Suematsu K, Naruke T, Shimozato Y. Lung cancer. Gan No Rinsho. 1967;13:227–38.PubMed Ishikawa S, Suematsu K, Naruke T, Shimozato Y. Lung cancer. Gan No Rinsho. 1967;13:227–38.PubMed
20.
Zurück zum Zitat Naruke T, Suemasu K, Ishikawa S. Lymph node mapping and curability at various levels of metastasis in resected lung cancer. J Thorac Cardiovasc Surg. 1978;76:832–9.PubMed Naruke T, Suemasu K, Ishikawa S. Lymph node mapping and curability at various levels of metastasis in resected lung cancer. J Thorac Cardiovasc Surg. 1978;76:832–9.PubMed
21.
Zurück zum Zitat Rusch VW, Asamura H, Watanabe H, Giroux DJ, Rami-Porta R, Goldstraw P. The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol. 2009;4:568–77.CrossRef Rusch VW, Asamura H, Watanabe H, Giroux DJ, Rami-Porta R, Goldstraw P. The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol. 2009;4:568–77.CrossRef
22.
Zurück zum Zitat Riquet M, Rivera C, Pricopi C, Arame A, Mordant P, Foucault C, et al. Is the lymphatic drainage of lung cancer lobe-specific? A surgical appraisal. Eur J Cardiothorac Surg. 2015;47:543–9.CrossRef Riquet M, Rivera C, Pricopi C, Arame A, Mordant P, Foucault C, et al. Is the lymphatic drainage of lung cancer lobe-specific? A surgical appraisal. Eur J Cardiothorac Surg. 2015;47:543–9.CrossRef
23.
Zurück zum Zitat Martini N. Mediastinal lymph node dissection for lung cancer. The memorial experience. Chest Surg Clin N Am. 1995;5:189–203.PubMed Martini N. Mediastinal lymph node dissection for lung cancer. The memorial experience. Chest Surg Clin N Am. 1995;5:189–203.PubMed
Metadaten
Titel
Clinicopathologic predictors of metastasis of different regional lymph nodes in patients intraoperatively diagnosed with stage-I non-small cell lung cancer
verfasst von
Fei Zhao
Fu-Xi Zhen
Yue Zhou
Chen-Jun Huang
Yue Yu
Jun Li
Qi-Fan Li
Cheng-Xiang Zhu
Xiao-Yu Yang
Shu-Hui You
Qian-Ge Wu
Xue-Yun Qin
Yi Liu
Liang Chen
Wei Wang
Publikationsdatum
01.12.2019
Verlag
BioMed Central
Erschienen in
BMC Cancer / Ausgabe 1/2019
Elektronische ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-019-5632-2

Weitere Artikel der Ausgabe 1/2019

BMC Cancer 1/2019 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.